Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Plaque Psoriasis Patients in Korea

Post-Marketing Surveillance Study of Adalimumab (Humira) for Pediatric Chronic Severe Plaque Psoriasis Patients According to the Standard for "Re-Examination of New Drugs"

The objective of this study is to evaluate the real world safety and effectiveness of adalimumab (Humira) for the treatment of Korean patients with pediatric chronic severe plaque psoriasis under a routine treatment practice.

Inclusion Criteria:

• Children and adolescents who are diagnosed with pediatric chronic severe plaque psoriasis.
• Prior to participating in the study, adalimumab treatment was determined according to clinical judgement of the physician.
• Participants (or legal representative) who voluntarily agreed to participate in this study and signed informed consent.

Exclusion Criteria:

• Participants with contraindication to adalimumab as listed in the approved Korean label.
• Participants with prior treatment with adalimumab.